What Is REGN Fair Value?
Regeneron Pharmaceuticals (REGN) fair value estimate using multiple valuation models, updated daily.
As of August 29, 2026, Regeneron Pharmaceuticals (REGN) has a composite fair value estimate of $1,810.30 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $794.19, suggesting the stock is undervalued by 127.9%.
Data as of August 29, 2026 (today)
Composite Fair Value
Undervalued4 of 4 models$1,810.30
vs. current price of $794.19(+127.9%)
How Is REGN Fair Value Calculated?
Four independent models estimate what REGN is worth. Each uses different inputs and assumptions. The composite blends them by weight.
REGN Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
35% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$3,325.25
+318.7%Undervalued
Inputs used
DDM (Dividend Discount Model)
15% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$393.05
-50.5%Overvalued
Inputs used
REGN Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
25% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$617.14
-22.3%Overvalued
Inputs used
PEG (Price/Earnings to Growth)
25% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$911.38
+14.8%Fair Value
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $794.19 is 318.7% below this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $3.95B | $3.75B |
| Year 2 | $4.63B | $4.16B |
| Year 3 | $5.41B | $4.61B |
| Year 4 | $6.34B | $5.12B |
| Year 5 | $7.41B | $5.68B |
| Year 6 | $8.68B | $6.30B |
| Year 7 | $10.15B | $6.99B |
| Year 8 | $11.88B | $7.75B |
| Year 9 | $13.90B | $8.60B |
| Year 10 | $16.27B | $9.54B |
| Terminal Value | $559.13B | $327.88B |
What Are REGN's Key Financial Metrics?
Earnings & Growth
Current Price
$794.19
EPS (TTM)
$39.71
Forward P/E
13.1
Profit Margin
27.9%
Cash & Balance Sheet
Free Cash Flow
3.1B
EBITDA
4.7B
Book Value
$316.11
Total Debt
2.7B
What Do Analysts Say About REGN?
Low
$730.00
Average
$840.43
High
$1,030.00
Upside
+5.8%
REGN Fair Value FAQ
What is the fair value of REGN?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), REGN's estimated fair value is $1,810.30. The stock is currently trading at $794.19, which makes it undervalued by our analysis.
How is REGN's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is REGN overvalued or undervalued?
Based on our analysis, REGN is undervalued. The current price of $794.19 is 127.9% below our estimated fair value of $1,810.30.
What do Wall Street analysts say about REGN?
27 analysts cover Regeneron Pharmaceuticals with a consensus rating of "Buy." The average price target is $840.43, ranging from $730.00 to $1,030.00. This implies 5.8% upside from the current price.